Clovis Luzivika Nzinga

8PUBLICATIONS
14CO-AUTHORS
Cardiology (incl. cardiovascular diseases)Predictive and prognostic markersDisease surveillanceNanomedicineOncology and carcinogenesis not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 16, 2023
Impaired health-related quality of life in the HCV cure era: who is concerned? (ANRS CO22 HEPATHER French cohort).

Patrizia Carrieri, Marc Bourlière, Vincent Di Beo

|Mar 09, 2023
Dynamic personalized prediction of the individual liver-related risk after sustained viral response in HCV patients.

Clémence Moreau, Marine Roux, Jérémie Riou

|Nov 29, 2022
Impact of direct-acting antiviral treatment for hepatitis C on cardiovascular diseases and extrahepatic cancers.

Laurent Lam, Hélène Fontaine, Nathanael Lapidus

|Apr 08, 2021
Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients-authors' reply.

Stanislas Pol, Clovis Lusivika Nzinga, Fabrice Carrat

|Feb 10, 2021
Editorial: similar risk of hepatocellular carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir-new clues from Europe. Authors' reply.

Stanislas Pol, Clovis Luzivika Nzinga, Hélène Fontaine

Pageof 2